Trials / Recruiting
RecruitingNCT06431490
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of TQB2102 for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2102 for injection | TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC) |
Timeline
- Start date
- 2024-07-22
- Primary completion
- 2027-05-01
- Completion
- 2029-12-01
- First posted
- 2024-05-28
- Last updated
- 2026-04-08
Locations
43 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06431490. Inclusion in this directory is not an endorsement.